How India Exports Etoposide to the World

In the United States, etoposide is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The drug has been available in generic forms for several years, facilitating its widespread use in oncology. Notably, on March 18, 2019, the FDA approved Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This approval underscores the continued relevance of etoposide in combination therapies. As of March 2026, there are no active FDA import alerts specifically targeting etoposide, indicating compliance with regulatory standards by Indian exporters. The substantial number of active exporters (237) reflects a competitive market, necessitating stringent adherence to FDA regulations to maintain market access.

Within the European Union, etoposide is subject to marketing authorization by the European Medicines Agency (EMA). The EMA has conducted periodic safety assessments, such as the one concluded in November 2023 (PSUSA/00001333/202302), to ensure the drug's continued safety and efficacy. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and monitoring of etoposide. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, ensuring product quality and safety. Indian exporters must align with these stringent standards to access and sustain their presence in these markets.

Etoposide is included in the World Health Organization's Model List of Essential Medicines, highlighting its critical role in cancer treatment globally. The drug is also subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is imperative for Indian manufacturers to ensure global acceptance and compliance with international quality benchmarks.

In India, etoposide is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, etoposide is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

The primary patents for etoposide have expired, leading to the availability of multiple generic versions and fostering a competitive market landscape. This generic competition has contributed to the drug's affordability and accessibility, both domestically and internationally.

In November 2023, the EMA concluded a periodic safety update report (PSUR) assessment for etoposide (PSUSA/00001333/202302), reaffirming its safety profile and therapeutic efficacy. This assessment is crucial for maintaining market authorization within the EU.

In January 2026, the EMA adopted a positive opinion recommending a change to the marketing authorization for Imfinzi (durvalumab), expanding its indications to include combination therapies with etoposide for certain cancers. This development underscores the ongoing integration of etoposide in novel therapeutic regimens.

These developments highlight the dynamic regulatory environment surrounding etoposide, emphasizing the need for continuous monitoring and compliance by Indian exporters to sustain and expand their global market presence.

Etoposide, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70–80% of India's API and KSM requirements are imported from China. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have underscored these risks. For instance, in March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to significant delays in the transportation of raw materials, including those essential for pharmaceutical manufacturing. These events highlight the fragility of supply chains dependent on single-country sources for critical raw materials.

Our proprietary trade data indicates that the top five Indian exporters of Etoposide account for 80.3% of total exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 44.5%. This high supplier concentration poses a significant risk; any operational disruptions within these key companies could severely impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. Notably, in November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are vital for antibiotic production. While these initiatives are steps toward diversification, their immediate impact on Etoposide's supply chain remains limited.

The geopolitical landscape significantly influences the Etoposide supply chain. In February 2026, the U.S. and Israel initiated military operations against Iran, leading to the effective shutdown of the Strait of Hormuz. This strait is a critical passage for global oil and chemical shipments, and its closure disrupted the supply of raw materials essential for pharmaceutical manufacturing.

Additionally, the Red Sea and the Strait of Hormuz have become hotspots for maritime threats, further complicating shipping routes. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued alerts regarding potential shortages of critical medications, including chemotherapeutic agents like Etoposide, due to these disruptions.

• Diversify Sourcing of KSMs and APIs: Establish alternative suppliers in different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production Capabilities: Invest in local manufacturing facilities for KSMs and APIs to strengthen supply chain resilience.

• Develop Strategic Stockpiles: Maintain reserves of critical raw materials and finished products to buffer against supply disruptions.

• Strengthen Supplier Relationships: Engage in long-term contracts and partnerships with multiple suppliers to ensure a stable supply chain.

• Implement Advanced Risk Monitoring Systems: Utilize real-time data analytics to anticipate and respond to geopolitical and logistical challenges promptly.

RISK_LEVEL: HIGH